Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti-estrogen

Abstract

Disclosed is that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype, by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the present disclosure finds that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.

1 . A method for treatment of ER-negative breast cancer in an individual in need thereof, said method comprising administering a therapeutically effective amount of an anti-PDGF-CC antibody and an anti-estrogen, to said individual either simultaneously or sequentially in any order, thereby treating the ER-negative breast cancer, wherein the anti-estrogen is selected from the group consisting of letrozole, fulvestrant, anastrozole, exemestane and toremifene. 
     
     
         2 . The method according to  claim 1 , wherein said treatment comprises the steps of:
 a. administration of the anti-PDGF-CC antibody to said individual in need thereof; and b. subsequent administration of the anti-estrogen.   
     
     
         3 . The-method according to  claim 1 , wherein the individual has suffered from ER-negative breast cancer, and wherein said breast cancer in said individual has been treated by surgery, and wherein said treatment reduces the risk of relapse. 
     
     
         4 . The method according to  claim 1 , wherein the first administration of anti-PDGF-CC antibody to said individual is prior to the first administration of said anti-estrogen. 
     
     
         5 . The method according to  claim 1 , wherein the anti-PDGF-CC antibody is a monoclonal antibody specifically binding PDGF-CC. 
     
     
         6 . The method according to  claim 1 , wherein the ER-negative breast cancer is a triple negative breast cancer. 
     
     
         7 . The method according to  claim 1 , wherein the ER-negative breast cancer is a basal-like breast cancer. 
     
     
         8 . The method according to  claim 1 , wherein the ER-negative breast cancer is a breast cancer wherein the primary tumor was ER-negative.